All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Dana-Farber Cancer Institute Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an anaplastic lymphoma kinase (ALK)-targeting moiety through a linker reported to be useful for the treatment of cancer.